ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas

Otology and Neurotology

Volumn 32, Issue 5, 2011, Pages 841-847

  Ahmad, Zana K ^a   Brown, Carrie M ^a   Cueva, Roberto A ^b   Ryan, Allen F ^a,c   Doherty, Joni K ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d Shohet Ear Associates   (United States)

Author keywords

Acoustic neuroma; AG825; Deafness; Dual ErbB inhibition; ErbB; ErbB activation; ErbB inhibition; ErbB1; ErbB2; ErbB3; Hearing loss; Lapatinib; Neurofibromatosis type 2; Phosphorylation; Tyrophostin; Tyrosine kinase inhibitor; Vestibular disorders; Vestibular nerve; Vestibular schwannoma

Indexed keywords

5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; BENZOTHIAZOLE DERIVATIVE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; LAPATINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TYRPHOSTIN;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; NEUROMA; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

BENZOTHIAZOLES; CELL CYCLE; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; HUMANS; NEUROMA, ACOUSTIC; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 79960017497     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0b013e31821f7d88     Document Type: Article

References (32)

1. Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-18. (Pubitemid 23007763)
2. Evans DG. Neurofibromatosis type 2: genetic and clinic features. ENT J 199;78:97-100.
3. Taschudi DC, Liinder TE, Fish U. Conservative management of unilateral acoustic neuromas. Am J Otol 2000;21:722-8.
4. Chang LS, Welling DB. Molecular biology of vestibular schwan-nomas. Methods Mol Biol 2009;493:163-77.
5. NeffBA, Welling DB, Akhmametyeva E, Chang LS. The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level. Otol Neurotol 2006;27:197-208.
6. Nelson MH, Dolder CR. Lapatinib: a novel dual tyrosine kinase inhib-itor with activity in solid tumors. Ann Pharmacother 2006;40:261-9. (Pubitemid 43269856)
7. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth factor receptors: a review ofclinical research with a focus on non-small cell lung cancer. Lancet Oncol 2003;4:397-406. (Pubitemid 36833681)
8. Doherty JK, Ongkeko O, Crawley B, Andalibi A, Ryan AF. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy. Otol Neurotol 2008;29:50-7.
9. Gross ME, Shazer RL, Agus DB. Targeting the HER-kinase axis in cancer. Semin Oncol 2004;31:9-20. (Pubitemid 38543936)
10. Harari PM, Allen GW, Bonner JA. Biology of interactions: anti-epidermal growth factor receptor agents. J Clin Oncol 2007;25: 4057-65. (Pubitemid 47492950)
11. Clark JJ, Provenzano M, Diggelmann HR, Xu N, Hansen SS, Hansen MR. The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a pre-liminary study. Otol Neurotol 2008;29:846-53.
12. Plotkin SR, Halpin C, McKenna MJ, et al. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neu-rotol 2010;31:1135-43.
13. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activa-tion of EGFR/ErbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-63.
14. Spector NL, Xia W, Bums H III, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advancedmalignancies. J Clin Oncol2005;23:2502-12. (Pubitemid 47050840)
15. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16. (Pubitemid 44036456)
16. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancertherapy. Oncogene 2000;19:6550-65. (Pubitemid 32197693)
17. Cohen BD, Kiener PA, Green JM, Foy L, Fell HP, Zhang K. The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. JBiol Chem 1996;271:30897-903. (Pubitemid 26404114)
18. Pavelic K, Banjac Z, Pavelic J, Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. AnticancerRes 1993;13:1133-7. (Pubitemid 23247476)
19. Menard S, Casalini P, Campiglio M, Pupa S, Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 2004;61:2965-78. (Pubitemid 40104594)
20. Slamon DJ, Godolphin W. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12. (Pubitemid 19147683)
21. Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 2007;7:257-68. (Pubitemid 46192173)
22. Burris HA III. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004;9:10-5.
23. Lin NU, Winer EP. Small molecule tyrosine kinase inhibitors. Breast Cancer Res 2004;6:204-10.
24. Zhou H, Kim Y-S, Peletier A, McCall W, Earp HS, Sartor CI. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 2004;58:344-52. (Pubitemid 38142458)
25. Xia W, Liu L-H, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer forma-tion with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004;23:646-53. (Pubitemid 38241266)
26. Grana TM, Sartor CI, Cox AD. Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the ras oncogene enhances radiation resistance. CancerRes 2003;63:7807-14. (Pubitemid 37466713)
27. Ammoun S, Cunliffe CH, Allen JC, et al. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol 2010;12:834-43.
28. Burris HA III, Hurwitz HI, Dees EC, et al. Phase I safety, phar-macokinetics, and clinical activity study oflapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic car-cinomas. J Clin Oncol 2005;23:5305-13. (Pubitemid 46206984)
29. Richter M, Zhang H. Receptor-targeted cancer therapy. DNA Cell Biol 2005;24:271-82. (Pubitemid 40656500)
30. Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epi-dermal growth factor receptor tyrosine kinases. Clin Ther 2008;30: 1426-47.
31. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathways for cancer drug discovery. Nature 2005; 4:899-1004.
32. JohnsonGL,LapadatR.Mitogen-activated protein kinase pathways- mediated by ERK, JNK, and p38 protein kinases. Science 2002;298: 1911-12. (Pubitemid 35425238)